8.07
-0.15(-1.82%)
Currency In USD
Address
7171 Rue Frederick Banting
Saint-Laurent, H4S 1Z9
Canada
Phone
514 332 4888
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
February 01, 2022
| Name | Title | Pay | Year Born |
| Mr. Ronald H. W. Cooper | President, Chief Executive Officer & Director | 963,267 | 1963 |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer | 341,754 | 1972 |
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer | 504,442 | 1986 |
| Ms. Tara Place M.B.A. | Senior Vice President of Human Resources | 0 | N/A |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary | 0 | 1980 |
| Mr. David Ryan Daws | Chief Financial Officer & Head of Business Development | 0 | 1974 |
| Mr. Matthew Boyd | Chief Regulatory Officer | 0 | N/A |
| Ms. Amy Pott | Chief Global Commercialization Officer | 0 | 1976 |
| Ms. Jill Buck | Chief Development Officer | 0 | 1974 |
| Ms. Joan Connolly | Chief Technology Officer | 0 | 1970 |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.